The GC Playbook
Subscribe
Sign in
Home
Notes
Chat
Archive
About
Latest
Top
Discussions
When Your Law Firm Shuts Down — The CLO’s Playbook for the Weil Dissolution THE GC PLAYBOOK In-House Intelligence for Life Sciences Legal
FROM THE EDITOR
5 hrs ago
•
John LaRocca
The Wrong File — What Amgen’s Vectibix Warning Letter Teaches About the Form 2253 Record
THE GC PLAYBOOK In-House Intelligence for Life Sciences Legal
Nov 15
•
John LaRocca
1
1
The Skinny Label Wins — What Hikma v. Amarin Means for the CLO
Justice Jackson's opinion drew a line the patent bar will spend years mapping.
Nov 11
•
John LaRocca
The 42% Problem — Why Your CEO Thinks Legal Contributes Nothing (And What to Do About It)
It is about how you are organizing the department, and whether the CEO sees legal as an enabler or a tollbooth.
Nov 8
•
John LaRocca
1
Read the Proclamation, Not the Headline
Section 232 Pharma Tariffs and Your Contracts
Nov 4
•
John LaRocca
1
The Regulator Now Talks to Your Investors
What the FDA–SEC MOU Does to Your Disclosure Program
Nov 1
•
John LaRocca
1
1
October 2026
Settling After the Loss — What the Liquidia/UTHR Agreement Actually Does
This article is about what happens after you lose.
Oct 28
•
John LaRocca
Pretextual — FDA's New Compounding Enforcement Theory and What It Means for Your Business FROM THE EDITOR
Is it Evidence f an Enforcement Shift?
Oct 25
•
John LaRocca
The CVR Is the Deal
A $12 CVR is not an incidental feature. It is the deal.
Oct 22
•
John LaRocca
1
Your Contract Lab’s Warning Letter Is Your Adulteration Problem
The adulteration follows as a matter of law.
Oct 18
•
John LaRocca
Your CDMO's Warning Letter Is Your Problem
The quality agreement in your file is not a defense. It’s evidence
Oct 14
•
John LaRocca
The AI Defense Didn't Work
FDA Just Issued Its First Warning Letter Citing AI Overreliance as a cGMP Failure. Your Compliance Team Is Next.
Oct 11
•
John LaRocca
1
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts